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The increasing number of patients suffering from different forms of cancer remains a 
major health problem in industrialized countries. Although commonly used as standard 
treatment options, surgery, radiation and classical chemotherapy often result in severe 
adverse reactions, or are even unsuccessful due to the emerging problem of resistance 
linked to various drugs. For this reason, oncology research is focused on the search for 
novel drugs which are highly specific and efficacious. In the last decade in particular, 
substances isolated from marine organisms have been considered for their anti-tumor 
activity. The purple ink of the sea hare Aplysia punctata acts as an effective defense 
mechanism against natural predators.  An active component of this ink, the 60 kDa A. 
punctata ink toxin (APIT) protein was isolated and subsequently analyzed for its 
cytotoxic activity. The aim of this work was to develop appropriate in vivo and in vitro 
model systems to evaluate the pharmacokinetics and cytotoxic/anti tumor activity of 
APIT. 
First the efficacy of this novel drug was assessed in vitro against various human cancer 
cell lines representing not only the most prevalent forms of cancer including lung, 
breast, prostate and colon carcinoma, but also different forms of leukemia and various 
treatment resistant cancer types. In cell culture experiments all tested cell lines were 
shown to be highly sensitive to APIT.  Both cancer cells of the hematopoietic system 
(Jurkat neo, CEM neo and K562) and cell lines representing solid tumors (GLC4, 
MCF7, SK-BR-3, PC3, DU145, HT29, RD-Es and A673) were efficiently killed by the 
cytotoxic activity of APIT. Very encouraging results were also obtained for the resistant 
cell lines GLC4/ADR and MCF7Bcl-XL. The concentration of APIT required to kill 50% 
of cells (inhibitory concentration-IC50) correlated well with the size of the cells and 
ranged between 3 and 12 ng/ml. Cells treated with APIT exhibit characteristic 
morphologies: adherent cell types lose their appendices and subsequently detach from 
neighboring cells, cells in suspension no form longer colonies, but exist individually 
instead. Both cell types were found to form vacuoles in their cytoplasm and exhibit an 
arrest in intracellular plasma and organelle movement. The additional/subsequent loss 
of metabolic activity and  permeablization of the cell membrane ultimately lead to cell 
death. 
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In order to examine the efficacy of APIT in vivo murine xenograft models were 
established. For this purpose, various cancer cell lines shown to be sensitive for APIT’s 
cytotoxic activity in vitro were injected subcutaneously into irradiated immuno deficient 
mice. After defining suitable experimental parameters, a cell concentration of 1 x 107 
cancer cells was found to be ideal to successfully establish subcutaneous tumors in the 
xenograft models. Xenograft models were implemented for the leukemia cell line CEM 
neo, the lung carcinoma cell line GLC4 and its multidrug resistant phenotype 
GLC4/ADR, for the colon carcinoma cell line HT29 and the sarcoma cell line A673, all 
of them exhibited a growth rate of at least 80%. The xenograft models established in 
this work has laid the foundations for future systematic investigations on the anti-tumor 
activity of APIT.  
 
